Across TCGA pan-cancer cohorts, MYO5A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO5A data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYO5A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO5A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, SCLC, and COAD are the cancer types where MYO5A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.773	0.626	.001	36	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.958	0.676	.013	6	view →
BRCA	OS	Median	All	0.218	0.579	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MYO5A tumor-vs-normal RNA expression · all MYO5A data types